Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Open in API
Filings indexed 2,318 across all filing types
Latest filing 2025-01-22 Regulatory Filings
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2025-01-22 English
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Legal Proceedings Report Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which is a regulatory requirement for listed companies to inform stock exchanges about material events. The content details ongoing legal proceedings and lawsuits involving the company, describing the status of motions to dismiss and court orders. It does not contain financial statements, management discussion, or detailed financial results. The document is an update on legal proceedings rather than a full legal report or a financial report. Given the nature of the content and the regulatory disclosure context, this fits best under Legal Proceedings Report (LTR). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS. Therefore, the classification is LTR with high confidence.
2025-01-22 English
6-K Filing
Regulatory Filings
2025-01-10 English
FORM 6-K
Regulatory Filings
2025-01-08 English
FORM 6-K
Regulatory Filings
2025-01-08 English
Earnings Call notification for Q3 FY2025
Earnings Release Classification · 95% confidence The document is a notification and press release about an upcoming earnings call and the release date of quarterly financial results (Q3FY25) for Dr. Reddy's Laboratories. It includes details about the earnings call schedule, dial-in information, and a summary of events related to the earnings announcement. There are no actual financial statements or detailed financial analysis included in the text. The document serves as an announcement of the earnings release and the earnings call, not the earnings release itself. Therefore, it fits the category of an Earnings Release (ER) announcement or notification. Given the content and length, it is best classified as an Earnings Release (ER) since it announces the upcoming release of quarterly results and the earnings call, which is typical for an ER filing type.
2025-01-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.